PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
 
Infect Immun. 1994 November; 62(11): 5168–5172.
PMCID: PMC303242

Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.

Abstract

We engineered an oral Shigella vaccine prototype that can invade intestinal epithelial cells but cannot undergo extensive intracellular replication or extend to adjacent epithelial cells. Strain CVD 1203, derived from wild-type Shigella flexneri 2a by introducing deletions in chromosomal aroA and invasion plasmid virG, was highly attenuated in the Sereny test. Two 10(9)-CFU orogastric doses (2 weeks apart) stimulated production of secretory immunoglobulin A antibodies to S. flexneri 2a and protected against conjunctival sac challenge with virulent S. flexneri 2a.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1021K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bernardini ML, Mounier J, d'Hauteville H, Coquis-Rondon M, Sansonetti PJ. Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin. Proc Natl Acad Sci U S A. 1989 May;86(10):3867–3871. [PubMed]
  • Blomfield IC, Vaughn V, Rest RF, Eisenstein BI. Allelic exchange in Escherichia coli using the Bacillus subtilis sacB gene and a temperature-sensitive pSC101 replicon. Mol Microbiol. 1991 Jun;5(6):1447–1457. [PubMed]
  • DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis. 1972 Jan;125(1):12–16. [PubMed]
  • Ferreccio C, Prado V, Ojeda A, Cayyazo M, Abrego P, Guers L, Levine MM. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol. 1991 Sep 15;134(6):614–627. [PubMed]
  • FORMAL SB, DAMMIN GJ, LABREC EH, SCHNEIDER H. Experimental Shigella infections: characteristics of a fatal infection produced in guinea pigs. J Bacteriol. 1958 May;75(5):604–610. [PMC free article] [PubMed]
  • Formal SB, Oaks EV, Olsen RE, Wingfield-Eggleston M, Snoy PJ, Cogan JP. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J Infect Dis. 1991 Sep;164(3):533–537. [PubMed]
  • Goldberg MB, Sansonetti PJ. Shigella subversion of the cellular cytoskeleton: a strategy for epithelial colonization. Infect Immun. 1993 Dec;61(12):4941–4946. [PMC free article] [PubMed]
  • Herrington DA, Van de Verg L, Formal SB, Hale TL, Tall BD, Cryz SJ, Tramont EC, Levine MM. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine. 1990 Aug;8(4):353–357. [PubMed]
  • Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine. 1991 Nov;9(11):810–816. [PubMed]
  • Jones PW, Dougan G, Hayward C, Mackensie N, Collins P, Chatfield SN. Oral vaccination of calves against experimental salmonellosis using a double aro mutant of Salmonella typhimurium. Vaccine. 1991 Jan;9(1):29–34. [PubMed]
  • Kärnell A, Cam PD, Verma N, Lindberg AA. AroD deletion attenuates Shigella flexneri strain 2457T and makes it a safe and efficacious oral vaccine in monkeys. Vaccine. 1993;11(8):830–836. [PubMed]
  • Kärnell A, Stocker BA, Katakura S, Reinholt FP, Lindberg AA. Live oral auxotrophic Shigella flexneri SFL124 vaccine with a deleted aroD gene: characterization and monkey protection studies. Vaccine. 1992;10(6):389–394. [PubMed]
  • Kärnell A, Stocker BA, Katakura S, Sweiha H, Reinholt FP, Cam PD, Trach DD, Lindberg AA. An auxotrophic live oral Shigella flexneri vaccine: development and testing. Rev Infect Dis. 1991 Mar-Apr;13 (Suppl 4):S357–S361. [PubMed]
  • Kotloff KL, Herrington DA, Hale TL, Newland JW, Van De Verg L, Cogan JP, Snoy PJ, Sadoff JC, Formal SB, Levine MM. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect Immun. 1992 Jun;60(6):2218–2224. [PMC free article] [PubMed]
  • Lett MC, Sasakawa C, Okada N, Sakai T, Makino S, Yamada M, Komatsu K, Yoshikawa M. virG, a plasmid-coded virulence gene of Shigella flexneri: identification of the virG protein and determination of the complete coding sequence. J Bacteriol. 1989 Jan;171(1):353–359. [PMC free article] [PubMed]
  • Levine MM, Dupont HL, Gangarosa EJ, Hornick RB, Snyder MJ, Libonati JP, Glaser K, Formal SB. Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines. Am J Epidemiol. 1972 Jul;96(1):40–49. [PubMed]
  • Levine MM, Gangarosa EJ, Werner M, Morris GK. Shigellosis in custodial institutions. 3. Prospective clinical and bacteriologic surveillance of children vaccinated with oral attenuated shigella vaccines. J Pediatr. 1974 Jun;84(6):803–806. [PubMed]
  • Li A, Pál T, Forsum U, Lindberg AA. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers. Vaccine. 1992;10(6):395–404. [PubMed]
  • Lindberg AA, Kärnell A, Stocker BA, Katakura S, Sweiha H, Reinholt FP. Development of an auxotrophic oral live Shigella flexneri vaccine. Vaccine. 1988 Apr;6(2):146–150. [PubMed]
  • Lindberg AA, Nord CE, Hellgren M, Sjöberg L. Identification of gram-negative aerobic fermentors in a clinical bacteriological laboratory. Med Microbiol Immunol. 1974 Mar 22;159(3):201–210. [PubMed]
  • Makino S, Sasakawa C, Kamata K, Kurata T, Yoshikawa M. A genetic determinant required for continuous reinfection of adjacent cells on large plasmid in S. flexneri 2a. Cell. 1986 Aug 15;46(4):551–555. [PubMed]
  • McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 1992;10(2):75–88. [PubMed]
  • Mel DM, Arsić BL, Nikolić BD, Radovanić ML. Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines. Bull World Health Organ. 1968;39(3):375–380. [PubMed]
  • Mel DM, Arsic BL, Radovanovic ML, Litvinjenko SA. Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbiol Acad Sci Hung. 1974;21(1-2):109–114. [PubMed]
  • Mel D, Gangarosa EJ, Radovanovic ML, Arsic BL, Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull World Health Organ. 1971;45(4):457–464. [PubMed]
  • Miller VL, Mekalanos JJ. A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J Bacteriol. 1988 Jun;170(6):2575–2583. [PMC free article] [PubMed]
  • Mills JA, Buysse JM, Oaks EV. Shigella flexneri invasion plasmid antigens B and C: epitope location and characterization with monoclonal antibodies. Infect Immun. 1988 Nov;56(11):2933–2941. [PMC free article] [PubMed]
  • Oaks EV, Hale TL, Formal SB. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect Immun. 1986 Jul;53(1):57–63. [PMC free article] [PubMed]
  • Oaks EV, Wingfield ME, Formal SB. Plaque formation by virulent Shigella flexneri. Infect Immun. 1985 Apr;48(1):124–129. [PMC free article] [PubMed]
  • Orr N, Robin G, Cohen D, Arnon R, Lowell GH. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun. 1993 Jun;61(6):2390–2395. [PMC free article] [PubMed]
  • Robertsson JA, Lindberg AA, Hoiseth S, Stocker BA. Salmonella typhimurium infection in calves: protection and survival of virulent challenge bacteria after immunization with live or inactivated vaccines. Infect Immun. 1983 Aug;41(2):742–750. [PMC free article] [PubMed]
  • Sansonetti PJ, Arondel J. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine. 1989 Oct;7(5):443–450. [PubMed]
  • Sansonetti PJ, Arondel J, Fontaine A, d'Hauteville H, Bernardini ML. OmpB (osmo-regulation) and icsA (cell-to-cell spread) mutants of Shigella flexneri: vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine. 1991 Jun;9(6):416–422. [PubMed]
  • SERENY B. Experimental keratoconjunctivitis shigellosa. Acta Microbiol Acad Sci Hung. 1957;4(4):367–376. [PubMed]
  • Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, Levine MM. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine. 1992;10(7):443–446. [PubMed]
  • Tsai CM, Frasch CE. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem. 1982 Jan 1;119(1):115–119. [PubMed]
  • Vasselon T, Mounier J, Hellio R, Sansonetti PJ. Movement along actin filaments of the perijunctional area and de novo polymerization of cellular actin are required for Shigella flexneri colonization of epithelial Caco-2 cell monolayers. Infect Immun. 1992 Mar;60(3):1031–1040. [PMC free article] [PubMed]
  • Verma NK, Lindberg AA. Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes. Vaccine. 1991 Jan;9(1):6–9. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)